Cara Therapeutics Inc (CARA) Shares Bought by Swiss National Bank
Swiss National Bank increased its stake in Cara Therapeutics Inc (NASDAQ:CARA) by 17.6% during the 3rd quarter, Holdings Channel reports. The firm owned 56,100 shares of the biopharmaceutical company’s stock after purchasing an additional 8,400 shares during the quarter. Swiss National Bank’s holdings in Cara Therapeutics were worth $1,344,000 at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of CARA. Cambridge Investment Research Advisors Inc. increased its holdings in shares of Cara Therapeutics by 27.1% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 26,452 shares of the biopharmaceutical company’s stock valued at $634,000 after acquiring an additional 5,646 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of Cara Therapeutics by 26.0% during the third quarter. Wells Fargo & Company MN now owns 112,079 shares of the biopharmaceutical company’s stock valued at $2,684,000 after acquiring an additional 23,130 shares in the last quarter. Adams Diversified Equity Fund Inc. bought a new position in shares of Cara Therapeutics during the third quarter valued at $410,000. Creative Planning bought a new position in shares of Cara Therapeutics during the third quarter valued at $207,000. Finally, First Quadrant L P CA bought a new position in shares of Cara Therapeutics during the third quarter valued at $393,000. Institutional investors own 60.62% of the company’s stock.
Several equities analysts have recently weighed in on the company. BidaskClub downgraded Cara Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 1st. Zacks Investment Research upgraded Cara Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 21st. HC Wainwright set a $26.00 price target on Cara Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 8th. Cantor Fitzgerald restated a “buy” rating and set a $27.00 price target on shares of Cara Therapeutics in a report on Thursday, October 4th. Finally, Stifel Nicolaus increased their price objective on Cara Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, August 8th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. Cara Therapeutics currently has a consensus rating of “Buy” and an average target price of $26.11.
Cara Therapeutics (NASDAQ:CARA) last released its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.05). The company had revenue of $5.06 million during the quarter, compared to the consensus estimate of $4.72 million. As a group, research analysts predict that Cara Therapeutics Inc will post -2.1 EPS for the current fiscal year.
In other Cara Therapeutics news, SVP Frederique Ph.D. Menzaghi sold 3,000 shares of the firm’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $23.99, for a total value of $71,970.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Derek T. Chalmers sold 20,000 shares of the firm’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $23.79, for a total value of $475,800.00. The disclosure for this sale can be found here. Insiders have sold 89,526 shares of company stock worth $1,830,672 over the last ninety days. 6.70% of the stock is currently owned by insiders.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
Read More: Cost of Debt
Want to see what other hedge funds are holding CARA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cara Therapeutics Inc (NASDAQ:CARA).
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.